• patients
  • In November 2016, Spotlight Innovation subsidiary Celtic Biotech Iowa received approval from the French National Agency for the Safety of Medicines and Health Products to commence Part 2 of the Phase 1 dose escalation safety study Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. (wikipedia.org)